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httpcense.Abstract Background: Fungal pulmonary infection can be acquired in tuberculosis, immunodeﬁ-
ciency patients, and other chronic diseases. Many physicians missed fungal pulmonary infection
because it does not show speciﬁc clinical manifestations. The aim was to identify the presence of
overlapping fungal infections in tuberculosis patients, using high multiplexing capacity of DNA
microarray.
Methods: The present study was conducted on 50 tuberculosis patients who were subdivided
into: Group I consisted of 30 cases of multidrug resistance tuberculosis, Group II consisted of 10
fresh cases and Group III consisted of 10 relapse cases. Morning sputum samples were examined
by DNA microarray.
Results: Aspergillus spp., was the only fungus detected in 24% of cases, Group I showed the
highest percentage (26.6%) with statistically signiﬁcant difference compared to Group II and III
(20%) for each. Aspergillus fumigatus was the predominant spp. identiﬁed followed by Aspergil-
lus niger and Aspergillus ﬂavus. Mixed infection was identiﬁed in 4 cases in Group I. A statistical
signiﬁcant association between fungal detection and MDR-TB, diabetic patients, smoker, being
male, presence of haemoptysis and toxic manifestations, presence of cavitary lesion or abscess
and severity of X-ray ﬁnding.com (N.M. Osman).
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152 N.M. Osman et al.Conclusion: Microarray detection of mycotic infection represents a rapid diagnostic tool helping
early diagnosis of fungal co-infection and pulmonary TB. MDR-TB patients carry the risk of higher
percentage of fungal infections and more liable for acquiring mixed fungal pathogens. Presence of
male sex, smoking, DM and far extent of lesion must attract physicians’ attention for fungal co-
infection with pulmonary TB.
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Fungal pulmonary infection has been emerging recently due to
widely used broad spectrum antibiotics and steroids [1]. It can
be acquired primarily or secondarily in tuberculosis (TB), immu-
nodeﬁciency patients, other chronic diseases such as diabetes
mellitus or malignancy, and may worsen the primary disease
[2–6]. TB is principally a disease of poverty, with 95% of cases
and 98% of deaths occurring in developing countries [7]. Glob-
ally, about 3% of all newly diagnosed patients have multidrug
resistance tuberculosis (MDR-TB) [8]. Egypt is ranked among
the mid level incidence countries in tuberculosis. In 2007 the an-
nual risk of infection was calculated mathematically by WHO it
was (24/1,00,000) [9]. In (2010), Egypt is estimated to have
15,000 TB cases and a rate of 18 cases per 1,00,000 of popula-
tion [10]. The percentage of mycotic infections increase in pul-
monary tuberculosis patients. Mainly four types of fungi, i.e.
Aspergillus niger, A. fumigatus, Histoplasma capsulatum and
Cryptococcus neoformans were recorded, which causes severe
infection in lungs in patients suffering from pulmonary tubercu-
losis [11]. Many physicians missed fungal pulmonary infection
because it does not show speciﬁc clinical manifestations and usu-
ally hindered by other diseases and cause high rates of morbidity
and mortality [12]. There is an increasing awareness amongst cli-
nicians and microbiologists pertaining to importance of infec-
tion caused by opportunistic fungi [13–15]. Therefore there is
an acute need for proper diagnosis of the opportunistic fungal
pathogen especially in tuberculosis patients. The conventional
identiﬁcation of pathogenic fungi based on phenotypic features
and physiological tests is time-consuming and, therefore, often
imperfect for the early initiation of an antifungal therapy [16].
DNA microarrays were introduced for the rapid and simulta-
neous identiﬁcation of different fungal species at the same time.
Based on pan fungal internal transcribed spacer (ITS) primers
directed at the conserved regions between the 18S and 28S
rRNA, which were shown to correlate well with culture results
[17]. Aim of the work: Is to identify the presence of overlapping
fungal infections in tuberculosis patients, using high multiplex-
ing capacity of DNA microarray which may help in correct
diagnosis of these diseases that may increase the cure rate.Patients and method
Subjects
The present study was conducted on 50 tuberculosis patients,
randomly selected amongst the diagnosed pulmonary tubercu-
losis cases admitted in El Abbasia Chest Hospital, They were
divided into the following groups:
 Group I consisted of 30 cases diagnosed as MDR-TB. Group II consisted of 10 cases diagnosed as new cases (fresh
cases).
 Group III consisted of 10 cases diagnosed as relapse cases.
Case deﬁnition by previous anti TB treatment [9].
New case
A patient who has never had treatment for TB or who has ta-
ken anti-TB drugs for less than 4 weeks.
Relapse
A patient who has been declared cured of any form of TB in
the past by a physician after one full course of chemotherapy,
and has become sputum smear-positive.
MDR-TB
It is deﬁned as resistance to any combination of anti-TB drugs
that include INH and rifampicin.
Cases were radiologically classiﬁed based on chest X-ray
(CXR) ﬁndings according to National Tuberculosis Associa-
tion of USA (196)1 [18] into: minimal, moderately advanced,
and far advanced cases.
Samples collection
Informed consent was obtained from each participant prior to
specimen collection. Early morning sputum was collected in a
sterile dry wide-necked, leak-proof container from each case
and transported to the laboratory.
Then sample was homogenized and liqueﬁed using
NALC––Na OH method that involves use of N-acetyl-L-cys-
teine (NALC) according to Colle et al. [19]. DNA extraction
was done using Qiamp DNAMini Kit (Qiagen, Izasa, Madrid,
Spain), the yield of total DNA obtained was determined spec-
trophotometrically. Universal fungal primers were used for
ampliﬁcation of the ITS1 and ITS2 regions. The sequence of
primers is ITS1: 50-TCCGTAGGTGAACCTGCGG-30 (posi-
tion 36–54) and ITS 4: 50-TCCTCCGCTTATTGATATG-30
(position 601–620), as described by White et al. [20]. The se-
quence of the forward primer ITS1 is complementary to a con-
served region at the end of the 18S rRNA gene, and the
sequence of the reverse primer ITS 4 binds to a conserved re-
gion at the beginning of the 28S rRNA gene [21]. DNA ampli-
ﬁcation was performed in parallel with positive and negative
controls. The positive control strain was isolated from clinical
sample. The clinical isolate was identiﬁed by standard methods
according to Colle et al. [19]. The negative control consisted of
an equal volume of water replacing the DNA template. A total
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contained 5 ll of 10· reaction buffer (100 mM Tris, 500 mM
kcl; pH 8.3), 3 ll of 25 mMMgCl2, 1 ll of 10 mM PCR Nucle-
otide mix, 2.5 ll of each primer (20 lM), 0.2 ll of Taq DNA
Polymerase (5 unit/ll) Biogenet – Korea, 500 ng of template
DNA and DEPC treated water. The ampliﬁcation was per-
formed in a Master cycler gradient (Eppendorf, Hamburg,
Germany). An initial denaturation step (94 C for 5 min) was
followed by 35 cycles (with each cycle consisting of DNA
denaturation at 94 C for 30 s, primer annealing at 57 C for
30 s, and elongation at 72 C for 1 min) and a ﬁnal extension
step at 72 C for 7 min [21]. Ampliﬁed DNA products were
separated by electrophoresis in a 1% agarose gel containing
ethidium bromide (0.5 mg/ml); the running buffer was TAE
(40 mM Tris acetate [pH 8.0], 1 mM EDTA). A 100-bp
DNA ladder was used as a molecular size marker (Promega
– USA). DNA bands were visualized by UV transillumination.
Then, DNA was denaturated for 5 min at 95 C and stored at
20 C. Conserved regions served as targets for probes which
are able to discriminate between C. neoformans, H. capsulatum
and Aspergillus (genus-speciﬁc probes) [21]. The probes were
purchased from TIB Molbiol, Germany in Table 1.
Five microlitres of each sample (PCR product) were spotted
on microarray slide at room temperature. Five slides were pre-
pared for each sample and tested by one of the ﬁve probes. Po-
sitive and negative controls were included. Probes were left at
room temperature to thaw, and then 100 ll of deionized H2O
were added to each probe. Hybridization was performed under
standardized conditions as described by Spiess et al. [22]. Slides
were incubated for 30 min at room temperature. After hybrid-
ization, the slides were washed with 2· SSC (1· is 0.15 M NaCl
plus 0.015 M sodium citrate) with 0.1% sodium dodecyl sul-
fate, then 2· SSC, and ﬁnally, 0.2· SSC for 10 min each time.
The washing procedure was performed at room temperature
with shaking in a glass container [21]. Staining of microarray
slides was done using ParagonT DNA Microarray QC Stain
Kit with SYBR R 555 Stain and Control Slide (Cat P32930)
– Invetrogen, USA, according to manufacturer‘s instructions.
Microarray slides were placed into a staining tube containing
the prepared staining solution (27 ml of stain buffer was added
to 30 ll SYBR Green nucleic acid stain concentrate). The
slides were incubated in the staining solution for 5 min at room
temperature. After the incubation, the staining solution was
poured off. Tubes (with slides inside) were centrifuged at
3000 rpm for 1 min with the tube lid off. Any remaining stain
solution was decanted. Twenty-seven milliliter of fresh wash
buffer were added and the slides were washed for 5 min with
mild shaking. The working wash buffer was poured off and
the slides were centrifuged at 3000 rpm for 1 min with the tube
lid off. Then the remaining wash buffer was poured off, and
centrifuged again for an additional 5 min with the tube lidTable 1 Oligonucleotide probes sequence for identiﬁcation of selec
Probes sequences
ACA AGA GAC GAC GGT AGC TTC ACG
GAACCCACCGCCCTCTTC
GGAGACACCACGAACTCTGT
CCAACACGAACACTGTCTGA
CCGACACCCAACTTTATTToff. Microarray slides were then read to be scanned. Each
microarray slide was imaged by Carl Zeis camera. Image anal-
ysis was performed by the Fluorescent image analyzer, Image
Pro-Plus to determine the optical density of each spot in addi-
tion to the positive and negative controls.
Data analysis
Analysis was performed using statistical software (SPSS ver-
sion 17; SPSS, Inc., Chicago, IL). Percentages, Chi square test
(v2) and correlation coefﬁcient test were used, with signiﬁcant
alpha level less than (0.05).
Results
The present study was conducted on 50 tuberculosis patients
admitted to El Abbasia Chest Hospital. Their age was ranging
from (25 to 65) years. The patients were divided into three
groups: Group I consisted of 30 cases diagnosed as MDR-
TB (60%) (20 males and 10 females). Group II consisted of
10 cases fresh diagnosed TB (20%) (8 males and 2 females).
Group III consisted of 10 cases with relapse of TB (20%) (8
males and 2 females).The presence of fungal infection in pul-
monary tuberculosis patients was detected by DNA micro-
array which allowed rapid and simultaneous identiﬁcation of
many fungal species at the same time. Aspergillus spp., was
the only type detected in this study, while other fungal species
as H. capsulatum or C. neoformans were not identiﬁed. Twelve
out of 50 cases (24%) were positive for Aspergillus spp., 8 cases
from Group I (26.6%), 2 cases from Group II (20%) and 2
cases from Group III (20%). Comparison between the studied
groups shows statistically signiﬁcant difference between Group
I and both Groups II and III, while no statistically signiﬁcant
difference was found between Group II and III as shown in
Table 2.
A. fumigatus was the predominant Aspergillus spp. identi-
ﬁed in all the patients followed by A. niger and A. ﬂavus. Dis-
tribution of the isolated fungal spp. among the studied groups
was as follows:
A. fumigatus was identiﬁed in 2 cases of Group I, 2 cases of
Group II and another 2 cases of Group III. While A. niger was
identiﬁed in 2 cases of Group I only. Mixed infection was iden-
tiﬁed in 4 cases in Group I only (two of them were A. fumigatus
with A. niger and the other two were A. fumigates with A. ﬂa-
vus) as shown in Table 3.
In the present study 22 patients were smokers, fungal infec-
tion was detected in 10 of them (45.5%). Out of 50 cases 6 were
suffering from DM, fungal infection was detected in 5 of them
(83.3%). Twenty-two patients were presented with haemopty-
sis and toxic manifestation, fungal infection was detected in 10ted fungal species.
Name Position
H. capsulatum 663–686
C. neoformans 540–565
A. ﬂavus 175–194
A. niger 114–133
A. fumigatus 502–520
Table 2 Prevalence of fungal infection among the studied groups.
Patients group Number of positive cases % Chi-square test value Signiﬁcance
Group I (MDRTB) 8 26.6 v2(1) 2 P< 0.05
(S)
Group II fresh TB 2 20 v2(2) 2 P< 0.05
(S)
Group III relapse TB 2 20 v2(3) 0 P> 0.05
(NS)
a v2(1) Comparison between patients of group I and group II.
b v2(2) Comparison between patients of group I and group III.
c v2(3) Comparison between patients of group II and group III.
Table 3 Prevalence of fungal species among the studied groups.
A. fumigatus A. niger A. fumigatus and A. niger A. fumigatus and A. ﬂavus
GroupI MDR-TB 2 2 2 2
Group II fresh TB 2 –
Group III relapsed TB 2 –
Table 4 Prevalence of fungal infection among the studied groups in relation to risk factors and clinical manifestations.
Variable Group I (MDR-TB) (30) Group II fresh TB (10) Group III relapsed TB (10)
No. No. of (+)ve fungal cases No. No. of (+)ve fungal cases No. No. of (+)ve fungal cases
Smoking 12 6 4 2 6 2
(DM) 4 3 0 0 2 2
Haemoptysis and toxic manifestations 12 6 6 2 4 2
154 N.M. Osman et al.of them (45.5%), their distribution among the studied groups
is shown in Table 4.
Based on chest X-ray ﬁndings cases were radiologically
classiﬁed into:
Minimal extent cases (6/50), moderately advanced cases
(20/50), fungal infection was detected in 4 of them (20%),
far advanced cases (24/50); fungal infection was detected in 8
of them (33.3%). Ten patients presented with cavitary lesions
or abscess, fungal infection was detected in 6 of them (60%)
as shown in Tables 5 and 6.
Table 7 showed that there was a statistically signiﬁcant cor-
relation between presence of fungal infection and male sex,
smoking, DM, presence of haemoptysis and toxic manifesta-
tions, presence of cavitary lesion or abscess and severity of
X-ray ﬁnding. While no statistically signiﬁcant correlation
was found between presence of fungal infection and age and
female sex.Discussion
Fungal infections remain a leading cause of infectious morbid-
ity and mortality in heavily immunosuppressed patients [23–
28]. For diagnosis of fungal infection, establishing cultures
from blood and bronchoalveolar lavage (BAL) samples is of-
ten unsuccessful due to the low yields of CFU, and in the caseof immuno-compromised high-risk patients who are febrile,
pulmonary tuberculosis, neutropenic, thrombocytopenic, and
often seriously ill, tissue biopsy specimens, in general, are
not available [29]. Early initiation of effective antifungal ther-
apy and reversal of underlying host defects remain the corner-
stones of treatment for pulmonary fungal infections [30]. More
sensitive and rapid detection assays of mycotic infections in
pulmonary tuberculosis patients have been established by use
of the PCR method. However, traditional methods in molecu-
lar biology generally work on a ‘‘one gene in one experiment’’
basis. Recently, DNA microarray has attracted tremendous
interests among biologists as it promises to monitor the whole
genome on a single chip. An experiment with a single DNA
chip can provide researchers information on thousands of
genes simultaneously [21].
The current study was carried upon 50 pulmonary tubercu-
losis patients; the presence of fungal infection in pulmonary
tuberculosis patients was detected by DNA microarray. Asper-
gillus spp., was the only type detected in this study in (24%) of
cases, while other fungal species as H. capsulatum or C. neo-
formans were not identiﬁed. Njunda et al. [31] found that the
prevalence of Aspergillus spp. in the sputum of patients sus-
pected of pulmonary tuberculosis was 15%, also, Kurhade
et al. [32] reported that the prevalence of Aspergillus spp.
was (16.26%). However Ekkena et al. [33] noticed that the
most common fungal isolates were Aspergillus spp. (42.9%).
Table 5 Prevalence of fungal infection among the studied groups in relation to radiological classiﬁcation.
Radiological extent Group I (MDR-TB) (30) Group II fresh TB (10) Group III elapsed TB (10)
No. No. of (+)ve fungal cases No. No. of (+)ve fungal cases No. No. of (+)ve fungal cases
Minimal 0 0 6 0 0 0
Moderate 12 4 0 0 8 0
Far 18 4 4 2 2 2
Table 6 Fungal detection in relation to cavitary status of the lesion.
Number of cases Patient with cavitary lesion or abscess (10) Patient without cavitary lesion or abscess (40)
No. of (+)ve fungal cases 6 60% 6 15%
No. of ()ve fungal cases 4 40% 34 85%
Table 7 Correlation coefﬁcient test correlating fungal detec-
tion in the studied cases and their variables.
Variable Correlation
coeﬃcient test r
Signiﬁcance
Age 0.2 P> 0.05 (NS)
Sex
Males 0.89 P< 0.05 (S)
Females 0.01 P> 0.05 (NS)
Smoking 0.99 P< 0.05 (S)
DM 0.93 P< 0.05 (S)
Haemoptysis and toxic
manifestations
0.87 P< 0.05 (S)
Presence of cavitary
lesion or abscess
0.95 P< 0.05 (S)
Radiologically far extent 0.94 P< 0.05 (S)
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attributed to the limited number of patients enrolled in the
present study and different geographical distribution. Patients
were positive for both pulmonary Mycobacterium tuberculosis
and Aspergillus sp. mainly, this established relationship was
also observed by Sahoo et al. [34] and a possible justiﬁcation
for this is the fact that tuberculosis remains the most important
cause of sub-acute and chronic respiratory morbidity which
most often leaves behind a scarred pulmonary parenchyma
vulnerable to fungal colonization.
In the present study the detected fungal species were in
higher percentage in MDR Group I (26.6%), than Group II
(20%) and Group III (20%). Comparison between the studied
groups shows statistically signiﬁcant difference between Group
I and both Groups II and III, while no statistically signiﬁcant
difference was found between Group II and III. Meawed et al.
[35] found that the prevalence of co-association between
retreatment of pulmonary TB and pulmonary fungal infection
was 30.8%. Study by Jain et al. [36] and Kurhde et al. [32] also
reported that in treated group, the fungal infection was found
in higher percentage than in the fresh group. They explained
that patients at the greatest risk for fungal infection are those
with prolonged periods of pulmonary tuberculosis. As com-
mon use of broad spectrum antibiotics in the pulmonary dis-
ease for long duration, for example in pulmonarytuberculosis stimulate the growth and virulence of infecting
fungus by destruction of competing bacterial ﬂora. Another
explanation for high susceptibility of MDR-TB patients to
fungal infection could be clariﬁed by understanding the immu-
nological changes associated with multi-drug resistant tubercu-
losis. It was conﬁrmed that the most important host defenses
against fungi are neutrophils and alveolar macrophages.
IFN-c produced by the T lymphocytes increases the produc-
tion of nitric oxide and other nitrogen and oxygen-reactive
radicals of macrophages [37]. It was observed that patients
with MDR-TB show low IFN-c production when compared
with patients with non-resistant tuberculosis before and after
treatment [38]. A recent study evaluating the immune response
of MDR-TB patients revealed that the T CD4+ cells of these
patients have a weaker response to stimulation with higher IL-
4 production and lower IFN-c response than fresh cases and
normal individuals. This observation suggesting that the T
CD4+ cells of MDRT patients polarize to Th2 response. Fur-
thermore, those patients had increased IL-10 and TGF-c cyto-
kine production that promote an environment, in which the
recently recruited cells of the immune system become refractory
to stimulation by the immunological activation signals [39].
The predominant Aspergillus species detected from sputum
in the present study was A. fumigatus detected in 10 cases, fol-
lowed by and A. niger detected in 4 patients, while A. ﬂavus
was detected from 2 patients. Among the collected samples 2
had mixed infection with A. fumigatus and A. niger and 2 had
mixed A. fumigatus and A. ﬂavus. These results were in accor-
dance with Kurhade et al. [32] who reported that A. fumigatus
was the commonest species isolated; followed by A. niger and
A. ﬂavus. Also Njunda et al. [31] reported that A. fumigatus
(5%) was the predominant Aspergillus species isolated from spu-
tum in their study followed by A. ﬂavus (3%). However Razmpa
et al. [40], reported higher prevalence for A. ﬂavus (30%). This
wide variation in the incidence and frequency of isolation of var-
ious Aspergillus species may be due to geographical differences
[41], different technologies used for identiﬁcation or number
of patients enrolled in the different studies.
It was noticed that the MDR group (Group I) carry the risk
of higher percentage of fungal infections and it was the only
group which was harboring mixed species. As treatment of
MDR group necessitate the use of different antibiotics and
anti-metabolites for long duration which may inﬂuence the
incidence of fungal infection.
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niﬁcant correlation between presence of fungal infection and
male sex, smoking, DM, presence of haemoptysis and toxic
manifestations, presence of cavitary lesion or abscess and
severity of X-ray ﬁnding. While no statistically signiﬁcant cor-
relation was found between presence of fungal infection and
age and female sex.
Men are more vulnerable to infection than females due to
their greater exposure to the surrounding. These results were
in agreement with that of Bansod and Rai [11], who observed
that fungal infection was higher in male (62.50%) as compared
to female (37.5%). They also reported positive correlation be-
tween fungal infection and severe toxemia and haemoptysis.
This study showed that there was a statistically signiﬁcant
correlation between presence of fungal infection, smoking
and DM. Smoking and DM act as a co-factor in accelerating
and amplifying the immumo-suppression state [42,43]. The
predominance of fungal infection in diabetic patients has been
reported by Jain et al. [36]. Khanna et al. [33] reported that fac-
tors mainly responsible for prevalence of fungal super infection
in pulmonary tuberculosis are presence of resistant strain,
chronicity of diseases, and associated disease such as diabetes
mellitus. The present study showed that, there was a statisti-
cally signiﬁcant correlation between presence of fungal infec-
tion and presence of cavitary lesion or abscess and severity
of X-ray ﬁnding. In the present study fungal infection was
higher (60%) in cavitary group than in the non cavitary group
(15%). This was in agreement with Jain et al. [36] who reported
that, fungus positivity was higher (59%) in cavitary group than
in the non cavitary group. Higher positivity was found accord-
ing to the extent of lesion but this difference was not statisti-
cally signiﬁcant (P> 0.05).
Conclusion
Microarray detection of mycotic infection represents a rapid
diagnostic tool helping early diagnosis of fungal co-infection
and pulmonary TB. MDR-TB patients carry the risk of higher
percentage of fungal infections and more liable for acquiring
mixed fungal pathogens. Presence of male sex, smoking, DM
and far extent of lesion must attract physicians’ attention for
fungal co-infection with pulmonary tuberculosis.
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